Sort   by:  
 Page size 
TranscriptomicsDifferential gene expression in RA synovial biopsies from responders versus non-responders to adalimumab therapy
TNF antagonists are routinely used in severe rheumatoid arthritis (RA) patients who failed conventional DMARD therapy. According to large clinical trials, the three available drugs (adalimumab, infliximab and etanercept) display similar effects in terms of efficacy, tolerability and side effects. Th...
ORGANISM(S): Homo sapiens 
2009-04-15 | E-GEOD-15602 | biostudies-arrayexpress
TranscriptomicsInvestigation of gene expression in biopsies from psoriasis patients before and after adalimumab treatment. Paired biopsies from non-lesional and lesional before treatment start and from psoriatic skin four and 14 days treatment start were included.
Gene expression in psoriatic skin has not previously been described as early as four days after treatment start. No clinical or histological changes are seen four days after treatment start but few genes have been shown to be regulated that early. We aimed to investigate changes in gene expression i...
ORGANISM(S): Homo sapiens 
2016-11-21 | E-MTAB-5262 | biostudies-arrayexpress
ProteomicsTear proteome of patients with non-infectious uveitis responders and non-responders to adalimumab
Proteomic anaysis of tear samples from patients with non-infectious uveitis responders and non-responders to adalimumab included in a cross-sectional study
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
MSV000095892 | MassIVE
Genomics
Adalimumab DMS Data
PRJNA953338 | ENA
TranscriptomicsRNA-Seq study of skin and blood samples from prospectively-recruited, deeply-phenotyped discovery and refinement psoriasis cohorts, during targeted treatment with adalimumab or ustekinumab
The Psoriasis Stratification to Optimise Relevant Therapy (PSORT) consortium, prospectively recruited deeply-phenotyped discovery and refinement psoriasis patient cohorts, during the early phase of treatment with two distinct biologics, adalimumab (TNF inhibitor) and ustekinumab (IL-12/23 inhibitor)...
ORGANISM(S): Homo sapiens 
2025-11-19 | E-MTAB-14509 | biostudies-arrayexpress
ClinicalLengthening Adalimumab Dosing Interval in Quiescent Crohn’s Disease Patients
Crohn’s disease is a chronic inflammatory bowel disease. This disease can be treated with, among other things, biologicals such as adalimumab. Patients use adalimumab for a long time to maintain remission and to prevent relapse of the bowel inflammation. The disadvantages of this therapy are the hig...
2245854 | ecrin-mdr-crc
ProteomicsThe Flash Oxidation (FOX) System: A Novel Laser-free Fast Photochemical Oxidation Protein Footprinting Platform
To validate the FOX flash photolysis system for hydroxyl radical footprinting of proteins experiments, TNF-alpha was oxidized in the presence and absence of a specific monoclonal antibody, adalimumab. The peptides that show decrease in oxidation correlate well with the known epitope for adalimumab.
ORGANISM(S): Homo sapiens (Human) 
2022-08-12 | PXD023169 | Pride
Flash photolysis Hrpf Tumor necrosis factor-alpha Mass spectrometry Fpop 
TranscriptomicsGene expression profiling in peripheral blood cells of patients with rheumatoid arthitis in response of anti-TNF-alpha
The goal of this study was to characterize the effects of anti-TNF-alpha treatments on gene expression in peripheral blood mononuclear cells. 8 women were submitted to a 12 weeks treatments with Etanercept or Adalimumab. Peripheral blood mononuclear cells were taken before and after the treatment. ...
ORGANISM(S): Homo sapiens 
2011-07-12 | E-GEOD-12897 | biostudies-arrayexpress
UnknownDemonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab.
Not available
S-EPMC10676336 | biostudies-literature
TranscriptomicsGuselkumab reduces disease- and mechanism-related biomarkers more than adalimumab in patients with psoriasis: a VOYAGE 1 substudy
In the phase 3 VOYAGE-1 trial (ClinicalTrials.gov identifier: NCT02207231), guselkumab demonstrated superior efficacy versus placebo and the tumor necrosis factor (TNF)-α antagonist, adalimumab, in patients with moderate-to-severe plaque psoriasis (Blauvelt et al., 2017). Here, skin samples were col...
ORGANISM(S): Homo sapiens 
2024-07-31 | GSE252029 | GEO
Sort   by:  
 Page size